Professor Sir Chris Evans’ ReNeuron cited as a regenerative medicine leader in UK Government's . 22/03/10

Guildford, UK, 22 March 2010: ReNeuron Group plc (LSE: RENE.L) is pleased to learn that it has been cited as a UK-based world leader in regenerative medicine in a new publication by the UK Government. The “Best of British” publication, produced by the Department for Business Innovation and Skills (BIS), showcases in a series of sector case studies the business sectors in which the UK leads on innovation, enterprise and technology. These are the sectors from which future UK economic growth and jobs are expected to be generated and include life sciences, digital communications and renewable energy, among others. Within life sciences, the case study refers to the importance of regenerative medicine and the UK’s pre-eminence in this field, giving the example of ReNeuron and its recently approved first-in-man clinical trial in the UK with ReN001, the Company’s stem cell therapy for disabled stroke patients. This trial, the world’s first of its kind using expanded neural stem cells in this indication, is due to commence shortly and will be conducted through the NHS system at a leading stroke treatment centre in Glasgow, Scotland.The “Best of British” publication forms part of an update given by the Government regarding its strategy to support the development of key new industries in the UK. The publication is available on the BIS website at www.bis.gov.uk. Michael Hunt, Chief Executive Officer of ReNeuron, said:“We are delighted to learn that the potential of our ground-breaking stem cell programmes has been recognised by the UK Government in this way. We are proud to be pioneering the translation of exciting stem cell science into clinical-stage therapeutics as a UK-based business, in collaboration with a number of leading UK academic institutions, hospitals and commercial organisations.”